Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression

In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment. 39 patients with Barrett's esophagus, seven of them wit...

Full description

Saved in:
Bibliographic Details
Published inEndoscopy Vol. 34; no. 12; p. 950
Main Authors Kahaleh, M, Van Laethem, J-L, Nagy, N, Cremer, M, Devière, J
Format Journal Article
LanguageEnglish
Published Germany 01.12.2002
Subjects
Online AccessGet more information

Cover

Loading…
Abstract In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment. 39 patients with Barrett's esophagus, seven of them with low-grade dysplasia, underwent APC and received 40 mg omeprazole daily for eradication of the metaplastic epithelium. After the treatment period, patients were randomly assigned to receive 20 or 40 mg omeprazole daily for long-term acid suppression. Histological and endoscopic changes were evaluated annually. Univariate and multivariate analyses were used to test the following 10 variables as predictors of sustained reversal of Barrett's esophagus at the end of follow-up: age, gender, length of diseased segment, presence of hiatal hernia, circumferential nature of lesion, presence of low-grade dysplasia at initial biopsy, number of coagulation sessions, result of pH monitoring under protein pump inhibitor (PPI) treatment, omeprazole dosage, and initial response to therapy (after 1 month). The median follow-up period was 36 months (range 12 - 48). The endoscopic and histological relapse rates at 1, 12, and 24 months, and end of follow-up were, respectively, 30 % and 44 % (12/39 and 17/39), 57 % and 54 % (16/28 and 15/28), 60 % and 57 % (17/28 and 16/28), and 62 % for both rates (23/37). According to multivariate analysis, shorter length of diseased segment and normalization of pH with PPI treatment were the only independent predictors of sustained long-term re-epithelialization. Among the seven patients with low-grade dysplasia, four experienced relapse after 1 month, and during the long-term follow-up, one was lost to follow-up and all the others experienced relapse, but only one developed low-grade dysplasia again. Cancer was found in two cases after 12 and 18 months, respectively. Persistence of acid reflux and greater length of diseased segment are the major factors associated with a high relapse rate after successful initial reversal. APC for ablation of Barrett's esophagus cannot be recommended.
AbstractList In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment. 39 patients with Barrett's esophagus, seven of them with low-grade dysplasia, underwent APC and received 40 mg omeprazole daily for eradication of the metaplastic epithelium. After the treatment period, patients were randomly assigned to receive 20 or 40 mg omeprazole daily for long-term acid suppression. Histological and endoscopic changes were evaluated annually. Univariate and multivariate analyses were used to test the following 10 variables as predictors of sustained reversal of Barrett's esophagus at the end of follow-up: age, gender, length of diseased segment, presence of hiatal hernia, circumferential nature of lesion, presence of low-grade dysplasia at initial biopsy, number of coagulation sessions, result of pH monitoring under protein pump inhibitor (PPI) treatment, omeprazole dosage, and initial response to therapy (after 1 month). The median follow-up period was 36 months (range 12 - 48). The endoscopic and histological relapse rates at 1, 12, and 24 months, and end of follow-up were, respectively, 30 % and 44 % (12/39 and 17/39), 57 % and 54 % (16/28 and 15/28), 60 % and 57 % (17/28 and 16/28), and 62 % for both rates (23/37). According to multivariate analysis, shorter length of diseased segment and normalization of pH with PPI treatment were the only independent predictors of sustained long-term re-epithelialization. Among the seven patients with low-grade dysplasia, four experienced relapse after 1 month, and during the long-term follow-up, one was lost to follow-up and all the others experienced relapse, but only one developed low-grade dysplasia again. Cancer was found in two cases after 12 and 18 months, respectively. Persistence of acid reflux and greater length of diseased segment are the major factors associated with a high relapse rate after successful initial reversal. APC for ablation of Barrett's esophagus cannot be recommended.
Author Kahaleh, M
Nagy, N
Van Laethem, J-L
Devière, J
Cremer, M
Author_xml – sequence: 1
  givenname: M
  surname: Kahaleh
  fullname: Kahaleh, M
  organization: Department of Gastroenterology, Hôpital Erasme (Université Libre de Bruxelles), Brussels, Belgium
– sequence: 2
  givenname: J-L
  surname: Van Laethem
  fullname: Van Laethem, J-L
– sequence: 3
  givenname: N
  surname: Nagy
  fullname: Nagy, N
– sequence: 4
  givenname: M
  surname: Cremer
  fullname: Cremer, M
– sequence: 5
  givenname: J
  surname: Devière
  fullname: Devière, J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12471537$$D View this record in MEDLINE/PubMed
BookMark eNo1kLtOwzAUhj0U0QtszOhsTAbbuTgdoeImVWIBia06sY9LUBJHtgPqG_DYBAHTf5O-4V-yWe97YuxMikspiuIqciWE4llR5XrGFkLIjGtVvs7ZMsb3nyhEcczmUuVaFplesK-t7_c8UejA-bb1n3wcAHsLDk3yIcIQyDYmNR8E3kEgM4ZAvSFoerjByad0EYGiH95wP0ZIgTCRhfoAGPa-h6HF2CEYP80tpmaqfvhoGgtxHCZ-jFN5wo4ctpFO_3TFXu5unzcPfPt0_7i53nKTyyrxWrnMSqeFtXVeF24tyQrnjFD1WpopIJHUwgmtC5crWzld5jZDvXYV2rJUK3b-yx3GuiO7G0LTYTjs_i9R35_WZqw
CitedBy_id crossref_primary_10_1016_j_giec_2009_07_008
crossref_primary_10_1016_S0016_5107_03_02380_0
crossref_primary_10_5009_gnl230094
crossref_primary_10_1111_j_1440_1746_2006_04369_x
crossref_primary_10_1586_17434440_2_6_713
crossref_primary_10_1016_j_gie_2005_07_017
crossref_primary_10_1016_j_gie_2009_07_026
crossref_primary_10_1080_00365520510023170
crossref_primary_10_1111_j_1572_0241_2006_00709_x
crossref_primary_10_1016_j_gie_2006_09_031
crossref_primary_10_1016_j_suc_2012_07_009
crossref_primary_10_1016_j_gie_2005_06_047
crossref_primary_10_1016_j_giec_2017_02_008
crossref_primary_10_3748_wjg_v23_i30_5508
crossref_primary_10_1371_journal_pone_0302204
crossref_primary_10_1097_01_mcg_0000152748_56902_02
crossref_primary_10_1097_01_pas_0000147403_33509_de
crossref_primary_10_1016_S1052_5157_03_00040_0
crossref_primary_10_1111_j_1445_2197_2012_06151_x
crossref_primary_10_1245_s10434_011_2163_8
crossref_primary_10_1136_pgmj_2006_054841
crossref_primary_10_1016_j_giec_2005_04_004
crossref_primary_10_1055_a_1203_5930
crossref_primary_10_1586_14737140_9_3_303
crossref_primary_10_1016_j_giec_2020_09_004
crossref_primary_10_1055_a_1230_5610
crossref_primary_10_1016_j_cdip_2005_12_002
crossref_primary_10_1111_j_1440_1746_2011_06768_x
crossref_primary_10_1038_ncpgasthep0214
crossref_primary_10_1111_j_1440_1746_2007_04832_x
crossref_primary_10_1016_j_bpg_2008_04_002
crossref_primary_10_1097_00001574_200307000_00011
crossref_primary_10_1016_S0016_5107_03_02002_9
crossref_primary_10_1016_j_tgie_2010_01_003
crossref_primary_10_1016_j_gie_2010_02_039
crossref_primary_10_1016_j_tgie_2005_04_001
crossref_primary_10_1111_den_13812
crossref_primary_10_1007_s10620_016_4315_y
crossref_primary_10_1093_dote_doac078
crossref_primary_10_1586_egh_10_20
crossref_primary_10_22516_25007440_422
crossref_primary_10_1111_j_1572_0241_2006_00706_x
crossref_primary_10_2165_00003495_200565001_00011
crossref_primary_10_1016_j_anchir_2005_11_006
crossref_primary_10_1016_j_soc_2009_03_003
crossref_primary_10_1007_s11894_017_0589_2
crossref_primary_10_1007_s10620_007_0023_y
crossref_primary_10_1016_j_giec_2006_12_003
crossref_primary_10_1016_S0016_5107_04_02576_3
crossref_primary_10_1159_000080318
crossref_primary_10_1038_ajg_2012_440
crossref_primary_10_1097_SLA_0b013e318133fa85
crossref_primary_10_1159_000357185
crossref_primary_10_1007_s10620_012_2313_2
crossref_primary_10_1111_j_1572_0241_2004_30228_x
crossref_primary_10_3748_wjg_v11_i8_1182
crossref_primary_10_1016_j_gie_2006_12_037
crossref_primary_10_1053_j_gastro_2009_02_062
crossref_primary_10_1111_j_1440_1746_2010_06421_x
crossref_primary_10_1038_ajg_2015_322
crossref_primary_10_22516_25007440_432
crossref_primary_10_1007_s10620_018_5066_8
crossref_primary_10_1038_nrgastro_2009_90
crossref_primary_10_1111_j_1442_2050_2004_00415_x
crossref_primary_10_1111_j_1365_2036_2007_03251_x
crossref_primary_10_1053_j_semtcvs_2005_10_004
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1055/s-2002-35847
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 12471537
Genre Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
123
1UC
3O-
4.4
53G
5RE
5~~
6PF
AAIWL
AAWTL
ABJNI
ABOCM
ABZLV
ACGFO
ACGFS
ACKTL
AENEX
AEVEF
AHRAW
AHRSK
AIVKU
AJGCD
AKJTW
ALMA_UNASSIGNED_HOLDINGS
BPGNG
CGR
CS3
CUY
CVF
EBS
ECM
EIF
EJD
EXEOM
F5P
FD8
H13
IY8
J5H
L7B
N9A
NPM
O9-
P2P
Q3R
QTC
RIG
ROL
RTC
UDS
X7M
ZGI
ZXP
ID FETCH-LOGICAL-c418t-b2f3d1f70ddb4b5f91ed0ffc02b91c1edaee170f0775f42d8f764d3a79f8ad662
ISSN 0013-726X
IngestDate Sat Sep 28 07:57:12 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-b2f3d1f70ddb4b5f91ed0ffc02b91c1edaee170f0775f42d8f764d3a79f8ad662
PMID 12471537
ParticipantIDs pubmed_primary_12471537
PublicationCentury 2000
PublicationDate 2002-12-01
PublicationDateYYYYMMDD 2002-12-01
PublicationDate_xml – month: 12
  year: 2002
  text: 2002-12-01
  day: 01
PublicationDecade 2000
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Endoscopy
PublicationTitleAlternate Endoscopy
PublicationYear 2002
References 12471547 - Endoscopy. 2002 Dec;34(12):1007-9
References_xml
SSID ssj0013005
Score 2.0648298
Snippet In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The...
SourceID pubmed
SourceType Index Database
StartPage 950
SubjectTerms Adult
Aged
Anti-Ulcer Agents - administration & dosage
Anti-Ulcer Agents - therapeutic use
Barrett Esophagus - pathology
Barrett Esophagus - therapy
Esophagoscopy
Female
Follow-Up Studies
Humans
Hydrogen-Ion Concentration
Laser Coagulation
Male
Middle Aged
Omeprazole - administration & dosage
Omeprazole - therapeutic use
Recurrence
Treatment Outcome
Title Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression
URI https://www.ncbi.nlm.nih.gov/pubmed/12471537
Volume 34
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLamICEuiL2s8gGJw8jgOE4cH1EFqoDOqUW9VY6X6RyaRJMZIfgFnPjNPC_JpAWkwiXKxBlPJt-Xl-e3IvTKFrxWViriWF4QXkgJz5zMSFkalQtmONV-oXi0KA9P-MfT4nQ2-zmJWtpu6jf6-x_zSv4HVTgGuPos2X9AdpwUDsA-4AtbQBi218L4c9ssiZetcwdwtl_JtgvOgKGJTrf2bpgQHAQ64dqb1mNR2VXjHQ0xRlf0c-t7Gajlto9x51EpVeslMKMD7fpCzXWrlqnRVyzvqldm3m-7FEbbXDLwN6b1yS6jsf6TOofX0Pkl2-sX3y5Y-WzjmKZNRiP0QsXsmdFHdOBNmOvdtwcbBZvEeyS5m-VEsNCzcJS7yYiZ-MUmUlTGWrS_SXda-EIYPQk_kXsH7_Q0wKa7CEiDziJAkl9j9Eqt7WFoD-2JysvLhbf9DD4pSsd-GP6_pDQKuKi300vyZWjTNFeWKkFlOb6L7qS1Bn4XiXMPzWxzH906StEUD9CPkT945A8GdHHiD97xB7cO7_iDVw1O_Hnd45E9OLEH199wYA-O7MET9oT5PXvwhD0P0cmH98cHhyR15iCaZ9WG1MzlJnOCGlPzunAys4Y6pymrZabhg7I2E9T5-oqOM1M5UXKTKyFdpUxZskfoRtM2dh_hnNpCZVIzxTVXtK4M1cIxk-dSSVDvn6DH8R6edbH8ytlwd5_-deQZur1j4XN008Hzbl-A8ripXwZMfwGS5XFf
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+follow-up+and+factors+predictive+of+recurrence+in+Barrett%27s+esophagus+treated+by+argon+plasma+coagulation+and+acid+suppression&rft.jtitle=Endoscopy&rft.au=Kahaleh%2C+M&rft.au=Van+Laethem%2C+J-L&rft.au=Nagy%2C+N&rft.au=Cremer%2C+M&rft.date=2002-12-01&rft.issn=0013-726X&rft.volume=34&rft.issue=12&rft.spage=950&rft_id=info:doi/10.1055%2Fs-2002-35847&rft_id=info%3Apmid%2F12471537&rft_id=info%3Apmid%2F12471537&rft.externalDocID=12471537
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-726X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-726X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-726X&client=summon